Black Diamond Therapeutics, Inc.(BDTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BDTX Black Diamond Therapeutics, Inc.

Closed New Year's Day 12-31 16:00:00 EST

2.14

-0.01

-0.47%

盘后2.14

+0.000.00%

17:31 EST

High2.24	Low2.14	Vol408.50K
Open2.19	D1 Closing2.15	Amplitude4.65%
Mkt Cap121.09M	Tradable Cap84.76M	Total Shares56.59M
T/O891.29K	T/O Rate1.03%	Tradable Shares39.61M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"BDTX","market":"US","secType":"STK","nameCN":"Black Diamond Therapeutics, Inc.","latestPrice":2.14,"timestamp":1735678800000,"preClose":2.15,"halted":0,"volume":408502,"hourTrading":{"tag":"盘后","latestPrice":2.14,"preClose":2.14,"latestTime":"17:31 EST","volume":726,"amount":1555.2514,"timestamp":1735684284550},"delay":0,"floatShares":39605447,"shares":56585063,"eps":-1.35865,"marketStatus":"Closed New Year's Day","change":-0.01,"latestTime":"12-31 16:00:00 EST","open":2.19,"high":2.24,"low":2.14,"amount":891287.637688,"amplitude":0.046512,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.35865,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1735808400000},"marketStatusCode":7,"adr":0,"listingDate":1580360400000,"exchange":"NASDAQ","adjPreClose":2.15,"preHourTrading":{"tag":"盘前","latestPrice":2.1997,"preClose":2.15,"latestTime":"08:52 EST","volume":772,"amount":1699.3941044,"timestamp":1735653144199},"postHourTrading":{"tag":"盘后","latestPrice":2.14,"preClose":2.14,"latestTime":"17:31 EST","volume":726,"amount":1555.2514,"timestamp":1735684284550},"volumeRatio":1.029126,"impliedVol":0.3368,"impliedVolPercentile":0.0278},"requestUrl":"/m/hq/s/BDTX/tweets","defaultTab":"tweets","newsList":[{"id":"2491135910","title":"US Penny Stocks Spotlight: Information Services Group Among 3 Top Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2491135910","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491135910?lang=en_us&edition=fundamental","pubTime":"2024-12-13 04:06","pubTimestamp":1734034006,"startTime":"0","endTime":"0","summary":"As the U.S. stock market experiences a pullback from its recent highs, investors are keeping a close eye on economic indicators and Federal Reserve actions that could influence future trends. In this context, penny stocks—though an older term—remain relevant as they often represent smaller or emerging companies with potential for growth. By focusing on those with strong financials and clear growth prospects, investors can uncover opportunities in this unique segment of the market.Overview: Information Services Group, Inc. is a technology research and advisory company operating in the Americas, Europe, and the Asia Pacific with a market cap of approximately $182.55 million.Take a closer look at Information Services Group's potential here in our financial health report.Understand Information Services Group's earnings outlook by examining our growth report.Overview: Black Diamond Therapeutics, Inc. is a clinical-stage oncology medicine company specializing in the discovery and development","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/._HFmWFPcwt6muyT_tZE7g--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b394072c431426666ba19d9f9857f297","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/._HFmWFPcwt6muyT_tZE7g--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b394072c431426666ba19d9f9857f297"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/us-penny-stocks-spotlight-information-200646696.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4209","SB","BABB","NAUT","BK4213","BK4021","BDTX","III","PVL","BK4563","BK4139","BK4134"],"gpt_icon":0},{"id":"2481670845","title":"Black Diamond Therapeutics Inc : Stifel Cuts Target Price to $16 From $18","url":"https://stock-news.laohu8.com/highlight/detail?id=2481670845","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481670845?lang=en_us&edition=fundamental","pubTime":"2024-11-06 20:03","pubTimestamp":1730894624,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241106:nFWN3MD17K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BDTX","BK4139"],"gpt_icon":0},{"id":"2481620067","title":"Black Diamond Theraptcs Price Target Maintained With a $11.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2481620067","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481620067?lang=en_us&edition=fundamental","pubTime":"2024-11-06 17:59","pubTimestamp":1730887140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BDTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 06, 2024 04:59 ET (09:59 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BDE","BDTX"],"gpt_icon":0},{"id":"2481825566","title":"Promising Clinical Outcomes and Financial Stability Support Buy Rating for Black Diamond Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2481825566","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481825566?lang=en_us&edition=fundamental","pubTime":"2024-11-06 00:15","pubTimestamp":1730823325,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Marc Frahm has maintained their bullish stance on BDTX stock, giving a Buy rating today. Marc Frahm’s rating is based on Black Dia...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-clinical-outcomes-and-financial-stability-support-buy-rating-for-black-diamond-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/promising-clinical-outcomes-and-financial-stability-support-buy-rating-for-black-diamond-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BDE","LENZ","BDTX"],"gpt_icon":0},{"id":"2481894986","title":"Strong Buy Rating for Black Diamond Therapeutics Driven by Financial Stability and Promising Clinical Developments","url":"https://stock-news.laohu8.com/highlight/detail?id=2481894986","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481894986?lang=en_us&edition=fundamental","pubTime":"2024-11-05 23:25","pubTimestamp":1730820310,"startTime":"0","endTime":"0","summary":"Analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Black Diamond Therapeutics (BDTX – Research Report), retaining the price target ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/strong-buy-rating-for-black-diamond-therapeutics-driven-by-financial-stability-and-promising-clinical-developments?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/strong-buy-rating-for-black-diamond-therapeutics-driven-by-financial-stability-and-promising-clinical-developments?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BDTX","BDE","LENZ"],"gpt_icon":0},{"id":"2481850245","title":"Black Diamond: Q3 Earnings Snapshot","url":"https://stock-news.laohu8.com/highlight/detail?id=2481850245","media":"Associated Press Finance","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481850245?lang=en_us&edition=fundamental","pubTime":"2024-11-05 22:00","pubTimestamp":1730815215,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass.  — CAMBRIDGE, Mass.  — Black Diamond Therapeutics, Inc.  on Tuesday reported a loss of $15.6 million in its third quarter.The Cambridge, Massachusetts-based company said it had a loss of 28 cents per share.The results beat Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of 37 cents per share.The company's shares closed at $2.99. A year ago, they were trading at $1.80.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/black-diamond-q3-earnings-snapshot-140015813.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BDTX","BDE"],"gpt_icon":0},{"id":"2481504587","title":"Vanda Pharmaceuticals Leads The Pack Of 3 US Penny Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2481504587","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481504587?lang=en_us&edition=fundamental","pubTime":"2024-11-05 21:10","pubTimestamp":1730812231,"startTime":"0","endTime":"0","summary":"As the U.S. stock market navigates the complexities of a presidential election and anticipated Federal Reserve rate decisions, investors are closely watching the movements of major indices like the Dow Jones and Nasdaq. In such a climate, penny stocks—though an older term—remain relevant for those seeking investment opportunities in smaller or newer companies. These stocks often offer potential value when supported by strong financials, presenting a unique opportunity for growth at lower price points.Vanda Pharmaceuticals, with a market cap of US$271.63 million and revenue of US$182.02 million, recently rejected a US$490 million acquisition offer from Cycle Pharmaceuticals, considering it undervalued. The company is debt-free and trades significantly below its estimated fair value, suggesting potential for appreciation. Despite being unprofitable with negative return on equity, Vanda's short-term assets comfortably cover both short- and long-term liabilities. The management team is exp","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vanda-pharmaceuticals-leads-pack-3-131031436.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BDTX","KLTR","BK4075","BK4023","RLX","VNDA","BK4213","PHX","BK4526","BK4563","BK4139","BABB","BK4209","BK4551","BK4539"],"gpt_icon":1},{"id":"2481850509","title":"Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2481850509","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481850509?lang=en_us&edition=fundamental","pubTime":"2024-11-05 21:00","pubTimestamp":1730811601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241105:nTUA1YQCJX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BDTX"],"gpt_icon":0},{"id":"2481564506","title":"Black Diamond Therapeutics Inc: Clinical Updates of Bdtx-1535 in Egfrm Nsclc and Regulatory Feedback Expected in Q1 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2481564506","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481564506?lang=en_us&edition=fundamental","pubTime":"2024-11-05 21:00","pubTimestamp":1730811601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241105:nTUA1YQCJX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BDTX"],"gpt_icon":0},{"id":"2481506887","title":"Black Diamond Therapeutics Q3 Basic EPS USD -0.28","url":"https://stock-news.laohu8.com/highlight/detail?id=2481506887","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481506887?lang=en_us&edition=fundamental","pubTime":"2024-11-05 21:00","pubTimestamp":1730811600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241105:nPLXE672DB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BDTX"],"gpt_icon":0},{"id":"2481506833","title":"Black Diamond Therapeutics Q3 Cash & Investments USD 112.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2481506833","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481506833?lang=en_us&edition=fundamental","pubTime":"2024-11-05 21:00","pubTimestamp":1730811600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241105:nPLXE672DB:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BDTX"],"gpt_icon":0},{"id":"2481450688","title":"Black Diamond Therapeutics Q3 Operating Expenses USD 18.13 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2481450688","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481450688?lang=en_us&edition=fundamental","pubTime":"2024-11-05 21:00","pubTimestamp":1730811600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241105:nPLXE672DB:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BDTX","BK4139"],"gpt_icon":0},{"id":"2481050435","title":"Black Diamond Therapeutics Q3 Income From Operations USD -18.13 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2481050435","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481050435?lang=en_us&edition=fundamental","pubTime":"2024-11-05 21:00","pubTimestamp":1730811600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241105:nPLXE672DB:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BDTX"],"gpt_icon":0},{"id":"2481166506","title":"Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2481166506","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481166506?lang=en_us&edition=fundamental","pubTime":"2024-11-05 21:00","pubTimestamp":1730811600,"startTime":"0","endTime":"0","summary":"Announced encouraging initial Phase 2 data of BDTX-1535 in patients with recurrent EGFRm NSCLC with a broad spectrum of classical, non-classical, and C797S resistance mutations in September 2024. Presented real-world treatment practices and patient outcomes in newly diagnosed NSCLC patients with non-classical EGFR mutations at the 2024 ESMO Congress. Clinical updates of BDTX-1535 in EGFRm NSCLC and regulatory feedback expected in Q1 2025. Cash, cash equivalents, and investments of $112.7 million as of September30, 2024; expected to be sufficient to fund operations into Q2 of 2026. In September 2024, Black Diamond presented a poster analyzing real-world treatment outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations  at the 2024 European Society for Medical Oncology  Congress. The analyses revealed the presence of a broad spectrum of NCMs, including PACC mutations, and allowed association with real-world treatment practices and therapeutic outcomes. Findings furt","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/BXvxt76gxDkYRmwEchGbew--~B/aD0yNTc7dz04Njc7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/518a8bb61ba367794514902f3e7e8df5","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/BXvxt76gxDkYRmwEchGbew--~B/aD0yNTc7dz04Njc7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/518a8bb61ba367794514902f3e7e8df5"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/black-diamond-therapeutics-reports-third-130000914.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BDE","BK4213","PR","BK4139","BDTX","LENZ"],"gpt_icon":0},{"id":"2481536570","title":"Black Diamond Therapeutics : Cash, Cash Equivalents, Investments of $112.7 Mln as of Sept 30; Expected to Fund Ops Into Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2481536570","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481536570?lang=en_us&edition=fundamental","pubTime":"2024-11-05 20:11","pubTimestamp":1730808702,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241105:nFWN3MC15Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BDTX","BK4139"],"gpt_icon":0},{"id":"2481570538","title":"Black Diamond Therapeutic's Cash, Cash Equivalents, And Investments Of $112.7M As Of September 30, 2024; Expected To Be Sufficient To Fund Operations Into Q2 Of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2481570538","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481570538?lang=en_us&edition=fundamental","pubTime":"2024-11-05 20:10","pubTimestamp":1730808652,"startTime":"0","endTime":"0","summary":"Black Diamond Therapeutic's Cash, Cash Equivalents, And Investments Of $112.7M As Of September 30, 2024; Expected To Be Sufficient To Fund Operations Into Q2 Of 2026","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/general/biotech/24/11/41741282/black-diamond-therapeutics-cash-cash-equivalents-and-investments-of-112-7m-as-of-september-30-202","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BDE","BDTX","BK4139"],"gpt_icon":0},{"id":"2481570582","title":"Black Diamond Therapeutic Q3 2024 GAAP EPS $(0.28) Beats $(0.38) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2481570582","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481570582?lang=en_us&edition=fundamental","pubTime":"2024-11-05 20:10","pubTimestamp":1730808632,"startTime":"0","endTime":"0","summary":"Black Diamond Therapeutic (NASDAQ:BDTX) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.38) by 26.32 percent. This is a 37.78 percent increase over losses of $(0.45) per","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41741266/black-diamond-therapeutic-q3-2024-gaap-eps-0-28-beats-0-38-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BDTX","BDE"],"gpt_icon":0},{"id":"2480629303","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2480629303","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480629303?lang=en_us&edition=fundamental","pubTime":"2024-11-04 19:00","pubTimestamp":1730718000,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Affiliated Mgrs Gp                               3Q      4.84    7:00 AM. ·Alph and Omg Sm                                 1Q       .22    4:01 PM. ·Altice USA Inc.                                 3Q       .04    4:05 PM. ·BRC Inc Class A                                 3Q      (.02)       AMC. ·Brkfld Asset Mgmnt                               3Q       .36    7:00 AM","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HPK","CHH","ABCL","CLF","APLE","JELD","CNTY","BOWL","NYT","EGHT","FWRD","ES","BWXT","BRK.A","ENTG","CRBG","EVEX","BDTX","HDSN","AOSL","CBT","INTA","PARR","HOLX","BRCC","HMN","CRGY","BWIN","KOS","AIG","AVB","GRPN","OGS","MAR","KE","GT","CEG","DTIL","CE","GKOS","PRAA","KRYS","NXPI","EQH","CNA","OPAD","CRUS","OMI","LSEA"],"gpt_icon":1},{"id":"2480884682","title":"Black Diamond Therapeutics Inc    expected to post a loss of 37 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2480884682","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480884682?lang=en_us&edition=fundamental","pubTime":"2024-11-01 22:09","pubTimestamp":1730470159,"startTime":"0","endTime":"0","summary":"* Black Diamond Therapeutics Inc     is expected to show no change in quarterly revenue when it reports  results on November 4 (estimated) for the period ending September 30 2024   *    * LSEG's mean ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BDE","BDTX"],"gpt_icon":0},{"id":"2480002548","title":"Black Diamond Therapeutics to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2480002548","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480002548?lang=en_us&edition=fundamental","pubTime":"2024-11-01 20:00","pubTimestamp":1730462400,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Nov. 01, 2024  -- Black Diamond Therapeutics, Inc. , a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows:. Stifel Healthcare Conference fireside chat at 4:10pm ET on Tuesday, November 19, 2024. Piper Sandler 36th Annual Healthcare Conference fireside chat at 3:00pm ET on Wednesday, December 4, 2024","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/BXvxt76gxDkYRmwEchGbew--~B/aD0yNTc7dz04Njc7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/518a8bb61ba367794514902f3e7e8df5","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/BXvxt76gxDkYRmwEchGbew--~B/aD0yNTc7dz04Njc7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/518a8bb61ba367794514902f3e7e8df5"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/black-diamond-therapeutics-participate-upcoming-120000585.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BDTX","LENZ","BDE"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.blackdiamondtherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0228},{"period":"1month","weight":-0.1925},{"period":"3month","weight":-0.463},{"period":"6month","weight":-0.518},{"period":"1year","weight":-0.2384},{"period":"ytd","weight":-0.2384}],"compareEarnings":[{"period":"1week","weight":-0.0253},{"period":"1month","weight":-0.0273},{"period":"3month","weight":0.0303},{"period":"6month","weight":0.0628},{"period":"1year","weight":0.233},{"period":"ytd","weight":0.233}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Black Diamond Therapeutics, Inc., a clinical-stage precision oncology medicine company, focuses on the discovery and development of therapies for patients with genetically defined cancers. The company's lead product candidate, BDTX-1535, a brain-penetrant, mutant selective, irreversible EGFR MasterKey inhibitor, designed to inhibit a family of oncogenic mutations, currently under Phase 1 clinical trial. It also develops BDTX-4933, a brain penetrant RAF MasterKey inhibitor, designed to be a brain penetrant and highly selective and potent inhibitor of oncogenic BRAF Class I, II, III and active RAF dimers, expected to initiate Phase 1 clinical trial. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.147109},{"month":2,"riseRate":0.4,"avgChangeRate":-0.093405},{"month":3,"riseRate":0.2,"avgChangeRate":-0.054754},{"month":4,"riseRate":0.6,"avgChangeRate":0.063032},{"month":5,"riseRate":0.4,"avgChangeRate":-0.11978},{"month":6,"riseRate":0.6,"avgChangeRate":0.430866},{"month":7,"riseRate":0.4,"avgChangeRate":-0.017528},{"month":8,"riseRate":0.6,"avgChangeRate":-0.018562},{"month":9,"riseRate":0.2,"avgChangeRate":-0.20342},{"month":10,"riseRate":0.4,"avgChangeRate":-0.080084},{"month":11,"riseRate":0.4,"avgChangeRate":-0.006676},{"month":12,"riseRate":0.2,"avgChangeRate":-0.057775}],"exchange":"NASDAQ","name":"Black Diamond Therapeutics, Inc.","nameEN":"Black Diamond Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Black Diamond Therapeutics, Inc.(BDTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Black Diamond Therapeutics, Inc.(BDTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Black Diamond Therapeutics, Inc.,BDTX,Black Diamond Therapeutics, Inc.股票,Black Diamond Therapeutics, Inc.股票老虎,Black Diamond Therapeutics, Inc.股票老虎国际,Black Diamond Therapeutics, Inc.行情,Black Diamond Therapeutics, Inc.股票行情,Black Diamond Therapeutics, Inc.股价,Black Diamond Therapeutics, Inc.股市,Black Diamond Therapeutics, Inc.股票价格,Black Diamond Therapeutics, Inc.股票交易,Black Diamond Therapeutics, Inc.股票购买,Black Diamond Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Black Diamond Therapeutics, Inc.(BDTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Black Diamond Therapeutics, Inc.(BDTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction